6533b81ffe1ef96bd1277d33

RESEARCH PRODUCT

Qualitative assessment of SARS-CoV-2-specific antibody avidity by lateral flow immunochromatographic IgG/IgM antibody assay.

Arantxa ValdiviaJosep FerrerEliseo AlbertArturo CarrataláJavier ColominaDavid NavarroMaría Jesús AlcarazDixie HuntleyIgnacio Torres

subject

AdultMaleCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Short CommunicationAntibody AffinityShort CommunicationsAntibodies ViralImmunoglobulin GSARS‐CoV‐2COVID-19 Serological Testing03 medical and health sciences0302 clinical medicineavidityVirologyurea dissociationMedicineHumansantibodiesIn patientAvidity030212 general & internal medicineQualitative ResearchAgedAged 80 and overImmunoassayCovid‐19medicine.diagnostic_testbiologybusiness.industrySARS-CoV-2COVID-19Middle AgedVirologySpecific antibodyInfectious DiseasesImmunoglobulin MImmunoglobulin MImmunoassayImmunoglobulin GImmunologybiology.protein030211 gastroenterology & hepatologyFemaleAntibodybusiness

description

Abstract Knowledge of the precise timing of SARS‐CoV‐2 infection may be of clinical and epidemiological relevance. The presence of low‐avidity IgGs has conventionally been considered an indicator of recent infection. Here, we carried out qualitative assessment of SARS‐CoV‐2‐specific antibody avidity using an urea (6M) dissociation test performed on a lateral flow immunochromatographic IgG/IgM device. We included a total of 76 serum specimens collected from 57 COVID‐19 patients, of which 39 tested positive for both IgG and IgM and 37 only for IgG. Sera losing IgG reactivity after urea treatment (n = 28) were drawn significantly earlier (P = .04) after onset of symptoms than those which preserved it (n = 48). This assay may be helpful to estimate the time of acquisition of infection in patients with mild to severe COVID‐19.

yearjournalcountryeditionlanguage
2020-08-02Journal of medical virology
10.1002/jmv.26344https://pubmed.ncbi.nlm.nih.gov/32706420